BRPI0409562A - tratamento de condições envolvendo placas amilóides - Google Patents
tratamento de condições envolvendo placas amilóidesInfo
- Publication number
- BRPI0409562A BRPI0409562A BRPI0409562-6A BRPI0409562A BRPI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- conditions involving
- amyloid plaques
- involving amyloid
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"TRATAMENTO DE CONDIçõES ENVOLVENDO PLACAS AMILóIDES". A invenção proporciona métodos para tratar doenças envolvendo deposição aberrante de peptídeo <225>-amilóide (A<225>), inclusive doença de Alzheimer, por meio da administração de antagonistas de receptores Nogo. A invenção também proporciona método para reduzir níveis de peptídeo A<225> em um mamífero por meio da administração de polipeptídeos receptores Nogo solúveis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46342403P | 2003-04-16 | 2003-04-16 | |
PCT/US2004/011728 WO2004093893A2 (en) | 2003-04-16 | 2004-04-16 | Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409562A true BRPI0409562A (pt) | 2006-04-18 |
Family
ID=33310776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409562-6A BRPI0409562A (pt) | 2003-04-16 | 2004-04-16 | tratamento de condições envolvendo placas amilóides |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070065429A1 (pt) |
EP (1) | EP1615654A2 (pt) |
JP (1) | JP2006523708A (pt) |
KR (1) | KR20060023959A (pt) |
CN (1) | CN1832752A (pt) |
AU (1) | AU2004231742A1 (pt) |
BR (1) | BRPI0409562A (pt) |
CA (1) | CA2522649A1 (pt) |
EA (1) | EA009643B1 (pt) |
IS (1) | IS8081A (pt) |
MX (1) | MXPA05011100A (pt) |
NO (1) | NO20055392L (pt) |
RS (1) | RS20050774A (pt) |
WO (1) | WO2004093893A2 (pt) |
ZA (1) | ZA200509242B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
PT1534736E (pt) * | 2002-08-10 | 2010-09-07 | Univ Yale | Antagonistas do receptor nogo |
US20080274112A1 (en) * | 2003-08-07 | 2008-11-06 | Lee Daniel H S | Nogo Receptor Antagonists |
PT1711530E (pt) * | 2003-12-22 | 2009-10-22 | Glaxo Group Ltd | Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas |
US20080045926A1 (en) * | 2004-01-30 | 2008-02-21 | Relton Jane K | Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists |
US8581147B2 (en) | 2005-03-24 | 2013-11-12 | Lincoln Global, Inc. | Three stage power source for electric ARC welding |
US9956639B2 (en) | 2005-02-07 | 2018-05-01 | Lincoln Global, Inc | Modular power source for electric ARC welding and output chopper |
US8785816B2 (en) | 2004-07-13 | 2014-07-22 | Lincoln Global, Inc. | Three stage power source for electric arc welding |
US8269141B2 (en) | 2004-07-13 | 2012-09-18 | Lincoln Global, Inc. | Power source for electric arc welding |
US9855620B2 (en) | 2005-02-07 | 2018-01-02 | Lincoln Global, Inc. | Welding system and method of welding |
US9647555B2 (en) | 2005-04-08 | 2017-05-09 | Lincoln Global, Inc. | Chopper output stage for arc welder power source |
BRPI0707276B1 (pt) | 2006-01-27 | 2021-08-31 | Biogen Ma Inc | Polipeptídeo de fusão antagonista de receptor nogo |
JP2010502623A (ja) * | 2006-08-31 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプターポリペプチドの末梢投与に関する方法 |
WO2009114197A2 (en) | 2008-03-13 | 2009-09-17 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) * | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4366241A (en) * | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
AU4682999A (en) * | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
GEP20063830B (en) * | 2000-01-12 | 2006-05-25 | Univ Yale | Nogo Receptor-Mediated Blockade of Axonal Growth |
US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
JP4465148B2 (ja) * | 2000-10-06 | 2010-05-19 | イェール ユニバーシティー | Nogoレセプターホモログ |
EP1423427A2 (en) * | 2001-08-27 | 2004-06-02 | Novartis AG | Nogo receptor homologues and their use |
US20050221420A1 (en) * | 2001-10-22 | 2005-10-06 | Carmen Barske | Nogo receptor homologues and their use |
PT1534736E (pt) * | 2002-08-10 | 2010-09-07 | Univ Yale | Antagonistas do receptor nogo |
US20080274112A1 (en) * | 2003-08-07 | 2008-11-06 | Lee Daniel H S | Nogo Receptor Antagonists |
-
2004
- 2004-04-16 MX MXPA05011100A patent/MXPA05011100A/es not_active Application Discontinuation
- 2004-04-16 US US10/553,669 patent/US20070065429A1/en not_active Abandoned
- 2004-04-16 KR KR1020057019510A patent/KR20060023959A/ko not_active Application Discontinuation
- 2004-04-16 WO PCT/US2004/011728 patent/WO2004093893A2/en active Application Filing
- 2004-04-16 EA EA200501620A patent/EA009643B1/ru not_active IP Right Cessation
- 2004-04-16 RS YUP-2005/0774A patent/RS20050774A/sr unknown
- 2004-04-16 EP EP04759905A patent/EP1615654A2/en not_active Ceased
- 2004-04-16 AU AU2004231742A patent/AU2004231742A1/en not_active Abandoned
- 2004-04-16 BR BRPI0409562-6A patent/BRPI0409562A/pt not_active IP Right Cessation
- 2004-04-16 JP JP2006510107A patent/JP2006523708A/ja active Pending
- 2004-04-16 CA CA002522649A patent/CA2522649A1/en not_active Abandoned
- 2004-04-16 CN CNA2004800169194A patent/CN1832752A/zh active Pending
-
2005
- 2005-10-21 IS IS8081A patent/IS8081A/is unknown
- 2005-11-15 NO NO20055392A patent/NO20055392L/no not_active Application Discontinuation
- 2005-11-15 ZA ZA200509242A patent/ZA200509242B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20055392L (no) | 2005-11-15 |
EA200501620A1 (ru) | 2006-06-30 |
JP2006523708A (ja) | 2006-10-19 |
CA2522649A1 (en) | 2004-11-04 |
WO2004093893A3 (en) | 2005-03-03 |
IS8081A (is) | 2005-10-21 |
EP1615654A2 (en) | 2006-01-18 |
MXPA05011100A (es) | 2006-04-18 |
EA009643B1 (ru) | 2008-02-28 |
CN1832752A (zh) | 2006-09-13 |
AU2004231742A1 (en) | 2004-11-04 |
RS20050774A (en) | 2007-12-31 |
AU2004231742A2 (en) | 2004-11-04 |
ZA200509242B (en) | 2006-12-27 |
WO2004093893A2 (en) | 2004-11-04 |
KR20060023959A (ko) | 2006-03-15 |
US20070065429A1 (en) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055392L (no) | Behandling av tilstander som omfatter amyloide plaque | |
EA200501891A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
EA200602015A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
DK1608350T3 (da) | Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
BRPI0416628A (pt) | uso de compostos orgánicos | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
UY29284A1 (es) | Anticuerpos ab(beta) humanizados usados en mejorar la cognicion | |
CY2015025I1 (el) | Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον | |
IL219709A0 (en) | Method and combination therapies for treating alzheimer's disease | |
CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
WO2006125227A3 (en) | Fibroblast activation protein inhibitor compounds and methods | |
BRPI0812504B8 (pt) | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero | |
BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
DE602005026169D1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
ATE534736T1 (de) | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
WO2006042745A3 (de) | Chemisch modifizierte iapp - peptidanaloga | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
DE60213629D1 (de) | Piperidinverbindungen als muscarinantagonisten | |
HK1081880A1 (en) | Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
AR068439A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
DK1670903T3 (da) | Behandling af neurodegenerative sygdomme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |